Clinical Trials


This is a Phase I/II, Open Label, Multicenter, Pilot Dose Escalation Study. The purpose of this study is to examine the safety, tolerability and efficacy of multiple doses of FFP104 in patients with Primary Biliary Cirrhosis (PBC). The study enrolled the first patients and is conducted in the UK, the Netherlands and Italy. The first results are expected in the second half of 2016. Identifier: NCT02193360